Corcept Therapeutics (CORT) Tops Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $114.92 -0.67%
EPS Growth %: +393.8%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +393.8%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $12 million versus the consensus estimate of $11.67 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Adobe Systems (ADBE) Tops Q3 EPS by 6c, Offers Guidance
- Copart (CPRT) Misses Q4 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
